10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012.

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number: 001-33930

IPC THE HOSPITALIST COMPANY, INC.

(Exact name of registrant as specified in its charter)

Delaware	95-4562058
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
4605 Lankershim Boulevard, Suite 617 North Hollywood, California	91602
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code: (888) 447-2362

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

As of October 23, 2012, there were 16,682,887 shares of the registrant’s common stock, $0.001 par value, outstanding.

IPC The Hospitalist Company, Inc.

FORM 10-Q

QUARTERLY REPORT

TABLE OF CONTENTS

		Page
	PART I
Item 1	Consolidated Financial Statements (unaudited)
	Consolidated Balance Sheets – September 30, 2012 and December 31, 2011		3
	Consolidated Statements of Income – Three and nine months ended September 30, 2012 and 2011		4
	Consolidated Statements of Cash Flows – Nine months ended September 30, 2012 and 2011		5
	Notes to Consolidated Financial Statements		6
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations		15
Item 3	Quantitative and Qualitative Disclosures about Market Risk		20
Item 4	Controls and Procedures		20
	PART II
Item 1	Legal Proceedings		21
Item 6	Exhibits		21
Signatures			22
Exhibit Index			23

Note: Items 1A, 2, 3, 4 and 5 of Part II are omitted because they are not applicable.

2

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

IPC The Hospitalist Company, Inc.

Consolidated Balance Sheets

(dollars in thousands, except for share data)

	September 30, 2012		December 31, 2011
Assets		(Unaudited)
Current assets:
Cash and cash equivalents	$	25,236	$	17,752
Accounts receivable, net		75,763		68,010
Insurance receivable for malpractice claims - current portion		10,075		8,693
Prepaid expenses and other current assets		8,028		13,139
Total current assets		119,102		107,594
Property and equipment, net		5,911		5,112
Goodwill		205,830		173,688
Other intangible assets, net		1,797		1,812
Deferred tax assets, net		1,522		1,522
Insurance receivable for malpractice claims - less current portion		17,685		15,186
Total assets	$	351,847	$	304,914
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities	$	3,776	$	3,962
Accrued compensation		29,437		21,640
Payables for practice acquisitions		23,706		23,724
Medical malpractice and self-insurance reserves, current portion		10,762		9,383
Deferred tax liabilities		750		750
Total current liabilities		68,431		59,459
Medical malpractice and self-insurance reserves, less current portion		37,274		32,803
Total liabilities		105,705		92,262
Stockholders’ equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued		0		0
Common stock, $0.001 par value, 50,000,000 shares authorized, 16,682,186 and 16,474,988 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively		17		16
Additional paid-in capital		148,931		139,579
Retained earnings		97,194		73,057
Total stockholders’ equity		246,142		212,652
Total liabilities and stockholders’ equity	$	351,847	$	304,914

The accompanying notes are an integral part of these consolidated financial statements.

3

IPC The Hospitalist Company, Inc.

Consolidated Statements of Income

(dollars in thousands, except for per share data)

(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Net revenue	$	127,651		$	114,485		$	385,916		$	339,604
Operating expenses:
Cost of services—physician practice salaries, benefits and other		93,570			84,920			282,675			248,801
General and administrative		20,689			18,081			61,195			54,275
Net change in fair value of contingent consideration		(3	)		178			511			658
Depreciation and amortization		1,027			824			2,848			2,374
Total operating expenses		115,283			104,003			347,229			306,108
Income from operations		12,368			10,482			38,687			33,496
Investment income		3			3			11			12
Interest expense		(78	)		(62	)		(252	)		(106	)
Income before income taxes		12,293			10,423			38,446			33,402
Income tax provision		4,501			3,961			14,309			12,693
Net income	$	7,792		$	6,462		$	24,137		$	20,709
Net income per share:
Basic	$	0.47		$	0.39		$	1.46		$	1.27
Diluted	$	0.46		$	0.38		$	1.42		$	1.23

The accompanying notes are an integral part of these consolidated financial statements.

4

IPC The Hospitalist Company, Inc.

Consolidated Statements of Cash Flows

(dollars in thousands)

(unaudited)

	Nine Months Ended September 30,
	2012			2011
Operating activities
Net income	$	24,137		$	20,709
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		2,848			2,374
Stock-based compensation expense		4,714			3,473
Net change in fair value of contingent consideration		511			658
Changes in assets and liabilities:
Accounts receivable		(7,753	)		(8,736	)
Prepaid expenses and other current assets		5,111			4,994
Accounts payable and accrued liabilities		(241	)		5
Accrued compensation		7,797			4,779
Medical malpractice and self-insurance reserves, net		1,969			2,777
Net cash provided by operating activities		39,093			31,033
Investing activities
Acquisitions of physician practices		(33,348	)		(19,387	)
Purchase of property and equipment		(2,955	)		(2,075	)
Net cash used in investing activities		(36,303	)		(21,462	)
Financing activities
Proceeds from long-term debt		15,000			0
Repayment of long-term debt		(15,000	)		0
Net proceeds from issuance of common stock		3,711			2,352
Excess tax benefits from stock-based compensation		983			1,177
Net cash provided by financing activities		4,694			3,529
Net increase in cash and cash equivalents		7,484			13,100
Cash and cash equivalents, beginning of period		17,752			18,935
Cash and cash equivalents, end of period	$	25,236		$	32,035
Supplemental disclosure of cash flow information
Cash paid for:
Interest	$	251		$	107
Income taxes	$	14,352		$	11,843

The accompanying notes are an integral part of these consolidated financial statements.

5

IPC The Hospitalist Company, Inc.

Notes to the Consolidated Financial Statements

(Unaudited)

September 30, 2012

Note 1. Operations and Significant Accounting Policies

Business

IPC The Hospitalist Company, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time hospitalist practices. Hospitalists focus on a patient’s care from the time of admission to discharge, working in close consultation with primary care physicians, other referring physicians and medical providers to coordinate the inpatient care delivery system and manage the entire inpatient episode of care. Our affiliated hospitalists practice in inpatient facilities, including acute care hospitals, long-term acute care facilities, specialty hospitals, psychiatric facilities and post-acute care facilities. The physicians are primarily full-time employees of our subsidiaries or consolidated professional medical corporations managed under long-term management agreements (Professional Medical Corporations), although part-time and temporary physicians are also employed or contracted on an as-needed basis. Also, unless otherwise expressly stated or the context otherwise requires, “our affiliated hospitalists” refer to physicians, nurse practitioners and physician assistants employed or contracted by either our wholly-owned subsidiaries or our Professional Medical Corporations. References to “practices” or “practice groups” refer to our Professional Medical Corporations and the wholly-owned subsidiaries of IPC that provide medical services, unless otherwise expressly stated or the context otherwise requires.

We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. In our opinion, these financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the following disclosures, when read in conjunction with the audited consolidated financial statements and notes thereto as of December 31, 2011, are adequate to make the information presented not misleading. For further information, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the SEC on February 23, 2012.

Principles of Consolidation

Our consolidated financial statements include the accounts of IPC The Hospitalist Company, Inc. and its wholly owned subsidiaries and consolidated Professional Medical Corporations managed under long-term management agreements. Some states have laws that prohibit business entities, such as IPC, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the “corporate practice of medicine”), or engaging in certain arrangements with physicians, such as fee-splitting. In states that have these restrictions, we operate by maintaining long-term management contracts with the Professional Medical Corporations, which are each owned and operated by physicians, and which employ or contract with additional physicians to provide hospitalist services. Under the management agreements, we provide and perform all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. The management agreements have an initial term of 20 years and are automatically renewable for successive 10-year periods unless terminated by either party for cause. The management agreements are not terminable by the Professional Medical Corporations, except in the case of gross negligence, fraud, or other illegal acts by us, or bankruptcy of IPC.

Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have controls over the operations of these VIE’s. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.

6

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment.

The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2012.

Fair Value of Financial Instruments

The carrying amounts of our cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

Accounts Receivable and Concentration of Credit Risk

For the nine months ended September 30, 2012 and 2011, total patient volume consisted of the following percentage from Medicare and Medicaid programs:

	Nine Months Ended September 30,
	2012			2011
Medicare and Medicaid patients		52	%		51	%

Our accounts receivable are stated at the amounts expected to be collected. Except with respect to the Medicare and Medicaid programs, concentrations of credit risk, which consist primarily of accounts receivable, is limited due to the large number of payors that compose our diverse payor mix and patient base. Accounts receivable from Medicare and Medicaid made up the following percentage of total net accounts receivable:

	September 30, 2012			December 31, 2011
Percentage of receivables from Medicare and Medicaid		36	%		36	%

Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill for the nine months ended September 30, 2012 are as follows (in thousands):

Goodwill - beginning balance at January 1, 2012	$	173,688
Goodwill acquired during period		32,142
Goodwill - ending balance at September 30, 2012	$	205,830

Medical Malpractice Liability Insurance

We maintain medical malpractice insurance coverage that indemnifies us and our employed health care professionals on a claims-made basis. Our claims-made coverage covers those claims reported during the policy period, which ends December 31 of each year, on a first dollar coverage up to our policy limits on new claims reported during the policy period. In December 2011, we renewed our annual professional liability insurance policy for 2012 effective January 1, 2012 under the same terms as our 2011 policy. We expect to be able to continue to obtain coverage in future years; however, there can be no assurance that we will obtain substantially similar coverage as is provided under the 2012 policy at acceptable costs and on favorable terms upon expiration.

7

We record our medical malpractice reserves, on an undiscounted basis, for self-insured deductibles, claims incurred and reported and claims incurred but not reported during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP.

Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

	September 30, 2012								December 31, 2011
	Assets		Liabilities						Assets		Liabilities
	Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities		Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities
Current Portion	$	10,075	$	10,252		510		10,762	$	8,693	$	8,956		427		9,383
Long-term Portion		17,685		17,685		19,589		37,274		15,186		15,186		17,617		32,803
Total	$	27,760	$	27,937		20,099		48,036	$	23,879	$	24,142		18,044		42,186

Recently Adopted Accounting Principles

In September 2011, the Financial Accounting Standard Board (FASB) issued a GAAP update on goodwill to allow an entity the option of performing a qualitative assessment before calculating the fair value of the reporting unit when testing goodwill for impairment. If the qualitative assessment concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the entity shall perform the quantitative two-step goodwill impairment test. Otherwise, the two-step goodwill impairment test is not required. We adopted this revised GAAP effective on January 1, 2012. The adoption of this revised GAAP does not have a material effect on our financial position, results of operations or cash flows.

In July 2011, the FASB issued a GAAP update on revenue recognition for certain health care entities that recognize significant amounts of patient service revenue without assessing the patient’s ability to pay. This revised GAAP requires such health care entities to present the provision for bad debt related to patient service revenue as a deduction from patient service revenue (net of contractual allowance and discounts) on their statement of income. It also requires additional disclosures of patient service revenue as well as qualitative and quantitative information about changes in the allowance for doubtful accounts. We adopted this revised GAAP effective on January 1, 2012. The adoption of this revised GAAP does not have a material effect on our financial position, results of operations or cash flows as we do not recognize a significant amount of revenue at the time services are rendered without assessing the patient’s ability to pay.

In May 2011, the FASB issued a GAAP update on fair value measurement, which eliminates certain differences between U.S. GAAP and International Financial Reporting Standards (IFRS), resulting in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between GAAP and IFRS. It also expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. We adopted this revised GAAP effective on January 1, 2012. The adoption of this revised GAAP does not have a material effect on our financial position, results of operations or cash flows.

Note 2. Acquisitions

We recognize all of the assets acquired, liabilities assumed and any contingent consideration at the acquisition-date fair value and expense all transaction related costs.

In connection with the acquisition of hospitalist physician practices, we generally record goodwill and other identifiable intangible assets consisting of physician and hospital agreements, which are amortized for tax purpose over 15 years. The results of operations of the acquired practices are included in the consolidated financial statements from the date of acquisition. In addition to the initial consideration paid at the close of these transactions, the asset purchase agreements generally provide for future consideration to be paid based upon the achievement of certain operating results of the acquired practices as of specified measurement dates. These additional payments are not contingent upon the future employment of the sellers. The estimated fair value of additional future consideration is recognized at the acquisition-date. Subsequent changes, if any, to the acquisition-date fair value are recognized as part of on-going operations.

During the nine months ended September 30, 2012, we completed the acquisition of assets of seven hospitalist physician practices. In addition to the initial consideration paid at the close of these transactions, five of the asset purchase agreements

8

provide for additional consideration to be paid based upon the future operating results of the acquired practices as of specified measurement dates. The contingent consideration for one acquisition was recorded on a provisional basis as of September 30, 2012, pending completion of the valuation study as of the acquisition date.

The following table summarizes the total amounts recorded during the nine months ended September 30, 2012, related to the acquisition of hospitalist practices (in thousands):

Acquired assets – paid and accrued:
Goodwill	$	32,142
Other intangible assets		677
Total acquired assets		32,819
Cash paid for acquisitions:
2012 transactions		(17,664	)
Contingent consideration		(15,660	)
Other - prior year transactions		(24	)
Total cash paid for acquisitions		(33,348	)
Decrease in payables for practice acquisitions		(529	)
Net change in fair value of contingent consideration		511
Net change in payables for practice acquisitions		(18	)
Payables for practice acquisitions, beginning of period		23,724
Payables for practice acquisitions, end of period	$	23,706

Our payable for practice acquisitions balance of $23,706,000 at September 30, 2012 is composed of $23,630,000 of accrued contingent consideration measured at fair value and $76,000 of liabilities recorded at undiscounted carrying value which approximates fair value.

Note 3. Debt

Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $75.0 million and contains an “accordion” feature that allows an increase of $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. In March 2012, we borrowed $15.0 million under the Credit Facility bearing interest at 1.0% per annum, which was repaid during the second quarter 2012. As of September 30, 2012, we had no borrowings outstanding, letters of credit of $0.2 million outstanding and $74.8 million available under the Credit Facility.

The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.25%, or the lender’s prime rate plus 0% to 0.25%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date.

The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of September 30, 2012, we were in compliance with such financial covenants and restrictions.

9

Note 4. Income Taxes

Following are the income tax provisions and effective tax rates for the three and nine months ended September 30, 2012 and 2011 (dollars in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Income tax provision	$	4,501		$	3,961		$	14,309		$	12,693
Effective tax rate		36.6	%		38.0	%		37.2	%		38.0	%

The decrease in the effective tax rate during 2012 as compared to the same period of 2011 was due primarily to a decrease in our effective state tax rate. The effective tax rates differ from the statutory U.S. federal income tax rate of 35.0% due primarily to state income taxes.

Our accounting policy is to include interest and penalties related to income tax liabilities in income tax expense. As of September 30, 2012, we did not have any estimated interest and penalties related to uncertain tax positions.

The tax years 2007 to 2011 remain open to examination by the major taxing jurisdictions to which we are subject. The statute of limitations for tax years 1997 to 2006 has expired, except that the tax years 1997 to 2002 are subject to adjustment of net operating losses by the Internal Revenue Service. We are subject to taxation in the United States and various state jurisdictions. A state examination has been initiated for one of our subsidiaries. The outcome of such examination cannot be predicted with certainty; however, we believe that the ultimate resolution will not have a material effect on our financial position, results of operations or cash flows.

We make our best estimate of the tax rate expected to be applicable for the full fiscal year. The rate so determined is used to compute our income tax expense for an interim period.

Note 5. Stock-Based Compensation

At September 30, 2012, we had a stock-based employee compensation program, for which we had reserved a total of 4,943,170 common shares for issuance under our 2007 and 2012 Equity Participation Plans (Equity Plan). Pursuant to our 2012 Equity Participation Plan, which was approved by our stockholders on June 7, 2012, a total of 1,422,130 shares of our common stock are available for issuance under such plan. Subsequent to the approval of our 2012 Equity Participation Plan, no new awards will be issued under the 2007 Equity Participation Plan. As of September 30, 2012, there were 1,425,666 shares of our common stock available for issuance under our Equity Plan, which included the canceled and forfeited shares issued prior to our 2012 Equity Participation Plan.

All option awards granted during the nine months ended September 30, 2012 were issued with exercise prices equal to the closing price of our common stock on the NASDAQ Global Select Market on the dates of grant. The options under our Equity Plan generally vest over a four-year period from date of grant, and unrestricted options terminate on the 10th anniversary of the agreement date. Restricted stock awards generally vest over a four-year period from date of the award and performance stock awards generally vest over two to three years from date of the award.

Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2012		2011		2012		2011
Stock-based compensation expense	$	1,626	$	1,222	$	4,714	$	3,473

10

As of September 30, 2012, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands).

	Total Unrecognized Compensation Cost		Weighted -average Remaining Contractual Term
			(Years)
Stock option	$	8,469		7.17
Restricted/Performance stock	$	2,813		3.00

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:

	Nine months ended September 30,
	2012			2011
Risk-free interest rate		1.21	%		2.55	%
Expected volatility		39.86	%		39.34	%
Expected option life (in years)		6.16			6.16
Expected dividend yield		0.00	%		0.00	%

The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero coupon issues. The expected volatility is based on historical volatility levels of our public company peer group and the volatility of our stock price since our initial public offering in January 2008. The expected option life of each award granted was calculated using the “simplified method” in accordance with GAAP.

The grant date fair value of each restricted stock award or performance stock award is based on the closing stock price on the grant date of the award as reported by NASDAQ Global Select Market.

The following table summarizes the stock option activities in our Equity Plan during the nine months ended September 30, 2012.

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
						(Years)		(in ,000)
Options outstanding as of December 31, 2011		1,581,332		$	25.92					$	11.02
Changes during period:
Granted		216,800			37.29						14.96
Exercised		(152,074	)		17.29						7.23
Cancelled/Forfeited		(856	)		1.40						0.27
Expired		(2,680	)		0.77						0.14
Options outstanding as of September 30, 2012		1,642,522		$	28.27		7.17	$	28,723	$	11.91
Options exercisable as of September 30, 2012		1,028,439		$	22.72		6.41	$	23,676	$	9.62

11

The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the nine months ended September 30, 2012.

	Shares			Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
				(Years)		(in ,000)
Restricted/performance stock awards outstanding as of December 31, 2011		31,496						$	40.87
Changes during period:
Granted		80,535							36.57
Released		(8,085	)						35.03
Restricted/performance stock awards outstanding as of September 30, 2012		103,946			3.00	$	4,750	$	37.99

Note 6. Earnings Per Share

Basic net income per share is calculated by dividing net income for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income for the period by the weighted average number of shares outstanding during the period plus the dilutive effect of our outstanding stock awards and shares issuable under our employee stock purchase plan using the treasury stock method.

The calculations of basic and diluted net income per share for the three and nine months ended September 30, 2012 and 2011 are as follows (dollars in thousands, except for per share data):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Basic:
Net income	$	7,792	$	6,462	$	24,137	$	20,709
Weighted average number of common shares outstanding		16,616,866		16,419,071		16,556,061		16,370,878
Basic net income per share	$	0.47	$	0.39	$	1.46	$	1.27
Diluted:
Net income	$	7,792	$	6,462	$	24,137	$	20,709
Weighted average number of common shares outstanding		16,616,866		16,419,071		16,556,061		16,370,878
Weighted average number of dilutive common shares equivalents		443,982		423,176		385,707		433,426
Common shares and common share equivalents		17,060,848		16,842,247		16,941,768		16,804,304
Diluted net income per share	$	0.46	$	0.38	$	1.42	$	1.23

Outstanding stock options with an exercise price above market are excluded from our diluted computation as their effect would be anti-dilutive. As of September 30, 2012, there were approximately 431,000 outstanding stock options with an exercise price above the average market price for the nine months ended September 30, 2012.

12

Note 7. Commitments and Contingencies

Legal

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated hospitalists. We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs.

We believe, based upon our review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, or cash flows in a future period.

Government Inquiry

On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We have produced responsive documents, will discuss with representatives of the government additional future productions to be made if requested and will continue to cooperate in the government investigation. We have been informed by the DOJ that a qui tam whistleblower complaint related to this investigation naming the Company has been filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also have been informed that several state attorneys general are examining our Medicaid claims in coordination with the DOJ. It is not possible to predict whether or when this matter may be resolved or what impact, if any, the outcome of this matter might have on our consolidated financial position, results of operations, or cash flows.

Note 8. Fair Value Measurement

Some of our assets and liabilities are measured and recorded at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The established fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (Levels 1 and 2) and the reporting entity’s own assumptions about market participant assumptions (Level 3). This hierarchy is used to measure fair value as follows:

• Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities.

• Level 2 inputs include quoted prices for similar assets and liabilities in active markets; quoted prices in markets that are not active; and other inputs that are observable or can be corroborated by observable market data for the asset or liability.

• Level 3 inputs are unobservable inputs for the asset or liability that are supported by little or no market activity.

The following table presents our liabilities measured at fair value on a recurring basis as of September 30, 2012 (in thousands):

	Quoted Price In Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Balance
Accrued contingent consideration for practice acquisitions (included in payables for practice acquisitions)	$	0	$	0	$	23,630	$	23,630

13

The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) for the three and nine months ended September 30, 2012 (in thousands):

	Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
Accrued contingent consideration for practice acquisitions
Beginning balance	$	17,191		$	23,624
Addition through acquisition transactions		6,537			15,155
Change in fair value realized		(3	)		511
Payments		(95	)		(15,660	)
Ending balance	$	23,630		$	23,630

Our payable for practice acquisitions totaling $23,706,000 at September 30, 2012, is composed of $23,630,000 of accrued contingent consideration measured at fair value and $76,000 of liabilities recorded at undiscounted carrying value which approximates fair value. The fair value of our accrued contingent consideration is determined using widely accepted valuation techniques, which include the income approach for estimating future consideration to be paid based on projected earnings of our acquired practices as of specified measurement dates. The income approach involves the use of a probability-weighted discounted cash flow model based on significant inputs not observable in the market. The significant inputs include a discount rate of 2.6%, and 100% probability of achieving the estimated projected earnings.

Because our accrued contingent consideration is generally based on a certain multiple of earnings of the acquired practices during a specified measurement period, a relatively small change in such projected earnings may result in a material change to the fair value of such contingent consideration liability with a corresponding adjustment to income from operations. We reassess our projected earnings and the related fair value of our accrued contingent consideration for practice acquisitions on a quarterly basis.

Note 9. Subsequent Events

Subsequent to September 30, 2012, we acquired the assets of two hospitalist physician practices.

14

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management’s discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission (SEC) on February 23, 2012.

The following discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding future events and the future results of IPC that are based on management’s current expectations, estimates, projections, and assumptions about our business. Words such as “may,” “will,” “could,” “should,” “target,” “potential,” “project,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “sees,” “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including, but not limited to, those discussed in our most recent Annual Report on Form 10-K, including the section entitled “Risk Factors,” as well as those discussed from time to time in the Company’s other SEC filings and reports. In addition, such statements could be affected by general industry and market conditions. Such forward-looking statements speak only as of the date of this Quarterly Report or, in the case of any document incorporated by reference, the date of that document, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this Report, or for changes made to this document by wire services or internet service providers. If we update or correct one or more forward-looking statements, investors and others should not conclude that we will make additional updates or corrections with respect to other forward-looking statements.

Overview and Recent Developments

We are a leading provider of hospitalist services in the United States. Hospitalist medicine is organized around inpatient care, primarily delivered in acute hospitals, but also in post-acute facilities, and is focused on providing, managing and coordinating the care of patients in facility based care settings. We believe we are the largest dedicated hospitalist company in the United States based on revenues, patient encounters and number of affiliated hospitalists. Our early entry into the emerging hospitalist industry has permitted us to establish a reputation and leadership position that we believe is closely identified with hospitalist medicine.

Acquisitions

During the nine months ended September 30, 2012, we acquired the assets of seven hospitalist physician practices for a total estimated purchase price of $32,819,000. In connection with these acquisitions, we recorded goodwill of $32,142,000 and identifiable intangible assets of $677,000. Total transaction costs of $209,000 for our acquisition activities during the nine months ended September 30, 2012 were expensed as incurred.

In connection with these acquisitions, we recorded liabilities of $15,155,000 representing the fair value of future contingent considerations to be paid based upon the estimated achievement of certain operating results of the acquired practices as of certain measurement dates. The fair value of such contingent considerations is re-evaluated on a quarterly basis based on changes in our estimate of the operating results of future payments. The changes, if any, in fair value are recognized in our results of operations.

Subsequent to September 30, 2012, we acquired the assets of two hospitalist physician practices.

Rate Changes by Government Sponsored Programs

The Medicare program reimburses for our services based upon the rates in the Medicare Physician Fee Schedule, and each year the Medicare program updates the Physician Fee Schedule reimbursement rates based on a formula approved by Congress in the Balanced Budget Act of 1997. Many private payors use the Medicare fee schedule to determine their own reimbursement rates.

The Medicare law requires the Centers for Medicare and Medicaid Services (CMS) to adjust the Physician Fee Schedule payment rates annually based on an update formula which includes application of the Sustainable Growth Rate (SGR) that was adopted in the Balanced Budget Act of 1997. This formula has yielded negative updates every year beginning in 2002, and numerous subsequent administrative and legislative actions since then have either delayed, modified or overrode the SGR formula to prevent the reimbursement reductions each year through 2012. CMS has determined that, effective January 1, 2012,

15

the SGR formula results in a payment cut of approximately 27 percent. Congress, however, enacted the Temporary Payroll Tax Cut Continuation Act of 2011, which blocked this cut through the end of February 2012. In February 2012, Congress passed the Middle Class Tax Relief and Job Creation Act of 2012, which blocks the cut through the end of 2012. While Congress has repeatedly intervened to mitigate the negative reimbursement impact associated with the SGR formula, there is no guarantee that Congress will continue to do so in the future. Moreover, the existing methodology may result in significant yearly fluctuations in the Physician Fee Schedule amounts, which may be unrelated to changes in the actual costs of providing physician services. Unless Congress enacts a change in the SGR methodology, the uncertainty regarding reimbursement rates and fluctuation will continue to exist.

Another provision that affects physician payments is an adjustment under the Medicare statute to reflect the geographic variation in the cost of delivering physician services, by comparing those costs to the national average. This concerns the “work” component of the Geographic Practice Cost Indices (GPCI). If Congress does not block this adjustment, payments would be decreased to any geographic area with an index of less than 1.0. Congress, however, enacted the Temporary Payroll Tax Cut Continuation Act of 2011, which blocked this cut through the end of February 2012. In February 2012, Congress passed the Middle Class Tax Relief and Job Creation Act of 2012, which blocks the cut through the end of 2012. Although Congress has extended the work GPCI floor several times, there is no guarantee that Congress will block the adjustment in the future, which could result in a decrease in payments we receive for physician services.

Congress has a strong interest in reducing the federal debt, which may lead to new proposals designed to achieve savings by altering payment policies. The Budget Control Act of 2011 (BCA) established a Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion. That Committee did not draft a proposal by the BCA’s deadline. As a result, automatic cuts in various federal programs are scheduled to take place, beginning in January 2013. Although the Medicare program’s eligibility and scope of benefits are generally exempt from these cuts, Medicare payments to providers are not exempt. The BCA does, however, provide that the Medicare cuts to providers may not exceed two percent. In September 2012, President Obama released a report providing estimates regarding the implementation of the BCA’s automatic cuts. Although the report did not provide many of the details about the cuts, it did confirm that Medicare payments to providers and health plans will be cut by 2 percent. The report estimated that the total cut to Medicare will be $11.09 billion for fiscal year 2013. At this time it is unclear how this automatic reduction may be applied to various Medicare healthcare programs, including physician reimbursement. Therefore it is not possible at this time to estimate what impact, if any, the BCA will have on our business or results of operations. However, under our provider compensation plan, any decrease in reimbursement rates also reduces our physician incentive payments such that, for example, a 2% net reduction in Medicare reimbursement rates for the codes applicable to the services performed by our affiliated hospitalists could reduce our net income by approximately 0.2%.

Healthcare Reform

In March 2010, the Patient Protection and Affordable Care Act (PPACA) and the Health Care and Education Reconciliation Act of 2010 (collectively the “Healthcare Reform Act”) were enacted. The Healthcare Reform Act includes a number of provisions that may affect our Company, although the impact of many of the changes will be unknown until they are implemented, which in some cases will not occur for a couple of years. The impact of some of these provisions may be positive, such as the expansion in the number of individuals with health insurance, the 10% Medicare bonus payment for primary care services (including outpatient and nursing home visits) from 2011 through 2015 to primary care practitioners for whom primary care services represented a minimum of 60% of Medicare allowed charges in a prior period, and the increase in Medicaid rates in 2013 and 2014 for primary care services. The impact of other provisions is unknown at this time, such as the establishment of an Independent Medicare Advisory Board that could recommend changes in payment for physicians under certain circumstances not earlier than January 15, 2014, which the Secretary of Health and Human Services generally would be required to implement unless Congress enacts superseding legislation. Fraud and abuse penalty increases and the expansion in the scope of the reach of the Federal Civil False Claims Act and government enforcement tools may adversely impact entities in the healthcare industry, including our Company.

The impact of certain provisions will depend upon the ultimate method of implementation. For example, the Healthcare Reform Act requires the Secretary of Health and Human Services to develop a budget neutral value-based payment modifier that provides for differential payment under the physician fee schedule for physicians or groups of physicians that is linked to quality of care furnished compared to cost. The Secretary of Health and Human Services has begun implementing the modifier through the proposed physician fee schedule rulemaking for 2013, by, among other things, specifying the proposed initial performance period and how it proposes to apply the proposed upward and downward modifier for certain physicians and physician groups beginning January 1, 2015, as well as all physicians and physician groups starting not later than January 1, 2017. The impact of this payment modifier cannot be determined at this time.

In addition, certain provisions of the Healthcare Reform Act authorize voluntary demonstration projects, which include the development of bundling payments for acute, inpatient hospital services, physician services, and post-acute services for episodes of hospital care beginning no later than 2013. In addition, the Healthcare Reform Act allows providers organized as Accountable Care Organizations that voluntarily meet quality thresholds to share in the cost savings they achieve for the Medicare program. The impact of these projects on our Company cannot be determined at this time.

16

Seasonality and Quarterly Fluctuations

We have historically experienced and expect to continue to experience quarterly fluctuations in net revenue and income from operations. Absent the impact and timing of acquisitions, our net revenue has historically been higher in the first and fourth quarters of the year primarily due to the following factors:

• the number of physicians we have on staff during the quarter, which may fluctuate based upon the timing of hires due to the end of the academic year for graduating resident physicians, the schedule of the Internal Medicine Board exams and terminations in our existing practices; and

• fluctuations in patient encounters, which are impacted by hospital census, which can be volatile, and physician productivity and often reflect seasonality due to the higher occurrence of illnesses such as flu and pneumonia in patient populations in the first quarter.

We have significant fixed operating costs, including physician practice salaries and benefits and, as a result, are highly dependent on patient encounters and the productivity of our affiliated hospitalists to sustain profitability. Additionally, quarterly results may be affected by the timing of practice acquisitions and the hiring and termination of our affiliated hospitalists.

Results of Operations and Operating Data

The following table sets forth operating data and selected consolidated statements of income information stated as a percentage of net revenue:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Operating data – patient encounters		1,349,000			1,193,000			4,049,000			3,538,000
Net revenue		100.0	%		100.0	%		100.0	%		100.0	%
Operating expenses:
Cost of services—physician practice salaries, benefits and other		73.3	%		74.2	%		73.2	%		73.3	%
General and administrative		16.2	%		15.8	%		15.9	%		16.0	%
Net change in fair value of contingent consideration		0.0	%		0.2	%		0.1	%		0.2	%
Depreciation and amortization		0.8	%		0.6	%		0.8	%		0.6	%
Total operating expenses		90.3	%		90.8	%		90.0	%		90.1	%
Income from operations		9.7	%		9.2	%		10.0	%		9.9	%
Investment income		0.0	%		0.0	%		0.0	%		0.0	%
Interest expense		(0.1	)%		(0.1	)%		0.0	%		(0.1	)%
Income before income taxes		9.6	%		9.1	%		10.0	%		9.8	%
Income tax provision		3.5	%		3.5	%		3.7	%		3.7	%
Net income		6.1	%		5.6	%		6.3	%		6.1	%

Three months ended September 30, 2012 compared to three months ended September 30, 2011

Our patient encounters for the three months ended September 30, 2012 increased by 156,000 encounters or 13.1% to 1,349,000, compared to 1,193,000 for the same period in the prior year. Net revenue for the three months ended September 30, 2012 was $127.7 million, an increase of $13.2 million, or 11.5%, from $114.5 million for the three months ended September 30, 2011. Of this $13.2 million increase, 60% was attributable to same-market area growth and 40% was

17

attributable to revenue generated from operations in five new markets. Of these new markets, three were entered through acquisitions in 2011, one was from a new hospital contract established in 2011 and one was from a new hospital contract established in 2012. Same-market encounters increased 9.7%, same-market revenue increased 7.0% and same-market patient revenue per encounter decreased 2.4%. The 2.4% decrease was principally due to a shift in service mix from acute to post acute care. Same-market areas are those geographic areas in which we have had operations for the entire current period and the entire comparable prior period. Because in-market area acquisitions are often small practice groups which become subsumed within our existing practice groups and are managed by our existing regional management staff, we consider these as part of our same-market area growth.

Physician practice salaries, benefits and other expenses for the three months ended September 30, 2012 were $93.6 million or 73.3% of net revenue compared to $84.9 million or 74.2% of net revenue for the three months ended September 30, 2011. These costs increased by $8.7 million or 10.2%. The increase in practice costs is largely related to the increase in the number of hospitalists added through hiring and acquisitions during the period and to continued investment in physician leadership initiatives. Same-market area physician costs increased a total of $4.6 million, which was primarily the result of increased costs related to our new hires or acquired physician practices. In addition, $4.1 million of the $8.7 million overall cost increase is attributable to physician costs associated with our entrance into five new markets.

General and administrative expenses include all salaries, benefits and operating expenses not specifically related to the day-to-day operations of our physician group practices, including billing and collections functions, our regional and market-area administrative offices and our corporate management and overhead. General and administrative expenses increased $2.6 million, or 14.4%, to $20.7 million, or 16.2% of net revenue, for the three months ended September 30, 2012, as compared to $18.1 million, or 15.8% of net revenue, for the three months ended September 30, 2011. The increase in expense was primarily the result of increased costs to support the continuing growth of our operations and acquisitions, including new regional office costs and other expenses. Excluding stock based compensation, which increased primarily as a result of the increase in our stock price at the date of various grants, general and administrative expenses were 14.9% of revenue for the three months ended September 30, 2012, compared to 14.7% of revenue for the same period of 2011.

Income from operations increased $1.9 million, or 18.0%, to $12.4 million from $10.5 million for the same period in the prior year. Our operating margin increased to 9.7% for the three months ended September 30, 2012, compared to 9.2% for the three months ended September 30, 2011.

Our effective tax rate for the three months ended September 30, 2012 was 36.6% compared to 38.0% for the three months ended September 30, 2011. The decrease in the effective tax rate is due primarily to a decrease in our effective state tax rate. The effective tax rate differs from the statutory U.S. federal rate of 35.0% due primarily to state income taxes.

Net income for the three months ended September 30, 2012 increased to $7.8 million from $6.5 million for the three months ended September 30, 2011, and our net income margin was 6.1% for the three months ended September 30, 2012, as compared to 5.6% for the same period in the prior year.

Nine months ended September 30, 2012 compared to nine months ended September 30, 2011

Our patient encounters for the nine months ended September 30, 2012 increased by 511,000 encounters or 14.4% to 4,049,000, compared to 3,538,000 for the same period in the prior year. Net revenue for the nine months ended September 30, 2012 was $385.9 million, an increase of $46.3 million, or 13.6%, from $339.6 million for the nine months ended September 30, 2011. Of this $46.3 million increase, 67% was attributable to same-market area growth and 33% was attributable to revenue generated from operations in five new markets. Of these new markets, three were entered through acquisitions in 2011, one was from a new hospital contract established in 2011 and one was from a new hospital contract established in 2012. Same-market encounters increased 11.1%, same-market revenue increased 9.3% and same-market patient revenue per encounter decreased 2.2%. The 2.2% decrease was principally due to a shift in service mix from acute to post acute care.

Physician practice salaries, benefits and other expenses for the nine months ended September 30, 2012 were $282.7 million or 73.2% of net revenue compared to $248.8 million or 73.3% of net revenue for the nine months ended September 30, 2011. These costs increased by $33.9 million or 13.6%. The increase in practice costs is largely related to the increase in the number of hospitalists added through hiring and acquisitions during the period and to continued investment in physician leadership initiatives. Same-market area physician costs increased a total of $22.4 million, which was primarily the result of increased costs related to our new hires or acquired physician practices. In addition, $11.5 million of the $33.9 million overall cost increase is attributable to physician costs associated with our entrance into five new markets.

18

General and administrative expenses increased $6.9 million, or 12.7%, to $61.2 million, or 15.9% of net revenue, for the nine months ended September 30, 2012, as compared to $54.3 million, or 16.0% of net revenue, for the nine months ended September 30, 2011. The increase in expense was primarily the result of increased costs to support the continuing growth of our operations and acquisitions, including new regional office costs and other expenses. Excluding stock based compensation, which increased primarily as a result of the increase in our stock price at the date of various grants, general and administrative expenses decreased by 40 basis points to 14.6% of revenue for the nine months ended September 30, 2012, compared to 15.0% of revenue for the same period of 2011.

Income from operations increased $5.2 million, or 15.5%, to $38.7 million from $33.5 million for the same period in the prior year. Our operating margin increased to 10.0% for the nine months ended September 30, 2012, compared to 9.9% for the three months ended September 30, 2011.

Our effective tax rate for the nine months ended September 30, 2012 was 37.2% compared to 38.0% for the nine months ended September 30, 2011. The decrease in the effective tax rate is due primarily to a decrease in our effective state tax rate. The effective tax rate differs from the statutory U.S. federal rate of 35.0% due primarily to state income taxes.

Net income for the nine months ended September 30, 2012 increased to $24.1 million from $20.7 million for the nine months ended September 30, 2011, and our net income margin increased to 6.3% for the nine months ended September 30, 2012, as compared to 6.1% for the same period in the prior year.

Liquidity and Capital Resources

As of September 30, 2012, we had no debt outstanding and approximately $100.0 million in liquidity, which is composed of $25.2 million in cash and cash equivalents and an available line of credit of $74.8 million.

Net cash provided by operating activities for the nine months ended September 30, 2012 was $39.1 million compared to $31.0 million for the same period of 2011. The primary changes in working capital during the nine months ended September 30, 2012 was composed of (i) an increase in accounts receivable of $7.8 million, (ii) a decrease of prepaid expenses and other current assets of $5.1 million, (iii) an increase in accrued compensation of $7.8 million primarily related to timing of payrolls and physician bonus payments, and (iv) an increase in medical malpractice and self-insurance reserves of $2.0 million.

Our days sales outstanding (DSO), which we use to measure the effectiveness of our collections, was 53 DSO as of September 30, 2012 as compared to 51 DSO as of December 31, 2011. We calculate our DSO using a three-month rolling average of net revenues. The increase in DSO was primarily related to revenues from new contracted facilities and practices acquired in 2012.

Net cash used in investing activities was $36.3 million for the nine months ended September 30, 2012, compared to $21.5 million for the same period in 2011. Cash of $33.3 million was used in the nine months ended September 30, 2012 for physician practice acquisitions and earn-out payments on prior acquisitions, compared to $19.4 million in the same period of the prior year. The remainder of cash used in investing activities was for purchases of computer hardware and software, and office furnishings.

For the nine months ended September 30, 2012, net cash provided by financing activities was $4.7 million, compared to $3.5 million provided by financing activities for the same period in 2011.

Credit Facility and Liquidity

Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $75.0 million and contains an “accordion” feature that allows an increase of $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. In March 2012, we borrowed $15.0 million under our Credit Facility bearing interest at 1.0% per annum, which was repaid during the second quarter 2012. As of September 30, 2012, we had no borrowings outstanding, letters of credit of $0.2 million outstanding and $74.8 million available under the Credit Facility.

The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.25%, or the lender’s prime rate plus 0% to 0.25%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date.

19

The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of September 30, 2012, we were in compliance with such financial covenants and restrictions.

We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Facility will be sufficient to finance our working capital requirements and fund anticipated acquisitions, contingent acquisition consideration and capital expenditures.

Off Balance Sheet Arrangements

As of September 30, 2012, we had no off-balance sheet arrangements.

Recently Adopted and New Accounting Principles

See Note 1 to the Consolidated Financial Statements for information regarding recently adopted accounting principles.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We had no outstanding borrowings under our Credit Facility at September 30, 2012.

Investments in both fixed rate and floating rate interest earning instruments carry a degree of interest rate risk. Fixed rate securities may have their fair market value adversely impacted due to a rise in interest rates, while floating rate securities with shorter maturities may produce less income if interest rates fall. As of September 30, 2012, all of our short-term investments were invested in money market funds with less than 90-day maturities and are classified as cash equivalents.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain controls and procedures designed to ensure that we are able to collect the information we are required to disclose in the reports we file with the Securities and Exchange Commission (SEC), and to process, summarize and disclose this information within the time periods specified in the rules of the SEC. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has conducted an evaluation of the design and operation of our “disclosure controls and procedures” as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the three months ended September 30, 2012 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

20

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Legal

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs.

We believe, based upon our review of pending actions and proceedings that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, or cash flows in a future period.

Government Inquiry

On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We have produced responsive documents, will discuss with representatives of the government additional future productions to be made if requested and will continue to cooperate in the government investigation. We have been informed by the DOJ that a qui tam whistleblower complaint related to this investigation naming the Company has been filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also have been informed that several state attorneys general are examining our Medicaid claims in coordination with the DOJ. It is not possible to predict whether or when this matter may be resolved or what impact, if any, the outcome of this matter might have on our consolidated financial position, results of operations, or cash flows.

ITEMS 1A, 2, 3, 4 AND 5 ARE NOT APPLICABLE

ITEM 6. EXHIBITS

(a) Exhibits

Exhibits required by Item 601 of Regulation S-K are listed in the Exhibit Index on page 23 of this report.

21

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the 30thday of October, 2012.

IPC THE HOSPITALIST COMPANY, INC.
By:	/S/ ADAM D. SINGER, M.D.
	Adam D. Singer, M.D.
	Chief Executive Officer
By:	/S/ RICK KLINE
	Rick Kline
	Chief Financial Officer

22

EXHIBIT INDEX

Exhibit Number	Description of Document
31.1	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes Oxley Act.
31.2	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes Oxley Act.
32.1	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act.
32.2	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

* Pursuant to Rule 406T of Regulation S-T, XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement or Prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

23

EX-31.1

Exhibit 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A)

OR RULE 15D-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Adam D. Singer, M.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of IPC The Hospitalist Company, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 30, 2012

/S/ ADAM D. SINGER, M.D.

Adam D. Singer, M.D.

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A)

OR RULE 15D-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Rick Kline, certify that:

1. I have reviewed this quarterly report on Form 10-Q of IPC The Hospitalist Company, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 30, 2012

/s/ RICK KLINE

Rick Kline

Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IPC The Hospitalist Company, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ ADAM D. SINGER, M.D.

Adam D. Singer, M.D.

Chief Executive Officer

Date: October 30, 2012

EX-32.2

Exhibit 32.2

CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IPC The Hospitalist Company, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ RICK KLINE

Rick Kline

Chief Financial Officer

Date: October 30, 2012

XML

Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payables for practice acquisitions)	$ 23,630,000
Quoted Price In Active Markets For Identical Instruments (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payables for practice acquisitions)	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payables for practice acquisitions)	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payables for practice acquisitions)	$ 23,630,000

XML

Schedule of Stock-Based Compensation Expense Recognized when Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Stock-based compensation expense	$ 1,626	$ 1,222	$ 4,714	$ 3,473

XML

Schedule of Changes in Carrying Amount of Goodwill (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012
Goodwill And Intangible Assets [Line Items]
Goodwill - beginning balance	$ 173,688
Goodwill acquired during period	32,142
Goodwill - ending balance	$ 205,830

XML

Subsequent Events - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2012 Hospitalist
Number of hospitalist physician practice acquired	2

XML

Summary of Restricted Stock Awards and Performance Stock Awards Activities in Equity Plan (Detail) (USD $)	9 Months Ended
	Sep. 30, 2012
Weighted Average Fair Value, Restricted/performance stock awards outstanding as of December 31, 2011	$ 40.87
Weighted Average Fair Value, Granted	$ 36.57
Weighted Average Fair Value, Released	$ 35.03
Weighted Average Fair Value, Restricted/performance stock awards outstanding as of September 30, 2012	$ 37.99
Shares, Restricted/performance stock awards outstanding as of December 31, 2011	31,496
Shares, Granted	80,535
Shares, Released	(8,085)
Shares, Restricted/performance stock awards outstanding as of September 30, 2012	103,946
Weighted-Average Remaining Contractual Term, Restricted/performance stock awards outstanding as of September 30, 2012 (Years)	3 years
Aggregate Intrinsic Value, Restricted/performance stock awards outstanding as of September 30, 2012	$ 4,750

XML

Income Taxes

9 Months Ended

Sep. 30, 2012

Income Taxes

Note 4. Income Taxes

Following are the income tax provisions and effective tax rates for the three and nine months ended September 30, 2012 and 2011 (dollars in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Income tax provision	$	4,501		$	3,961		$	14,309		$	12,693
Effective tax rate		36.6	%		38.0	%		37.2	%		38.0	%

The decrease in the effective tax rate during 2012 as compared to the same period of 2011 was due primarily to a decrease in our effective state tax rate. The effective tax rates differ from the statutory U.S. federal income tax rate of 35.0% due primarily to state income taxes.

Our accounting policy is to include interest and penalties related to income tax liabilities in income tax expense. As of September 30, 2012, we did not have any estimated interest and penalties related to uncertain tax positions.

The tax years 2007 to 2011 remain open to examination by the major taxing jurisdictions to which we are subject. The statute of limitations for tax years 1997 to 2006 has expired, except that the tax years 1997 to 2002 are subject to adjustment of net operating losses by the Internal Revenue Service. We are subject to taxation in the United States and various state jurisdictions. A state examination has been initiated for one of our subsidiaries. The outcome of such examination cannot be predicted with certainty; however, we believe that the ultimate resolution will not have a material effect on our financial position, results of operations or cash flows.

We make our best estimate of the tax rate expected to be applicable for the full fiscal year. The rate so determined is used to compute our income tax expense for an interim period.

XML

Debt - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended	9 Months Ended
	Mar. 31, 2012	Sep. 30, 2012
Line of Credit Facility [Line Items]
Maturity date of Credit Facility		Aug. 04, 2016
Interest rate terms		Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.25%, or the lender's prime rate plus 0% to 0.25%, both based on a leverage ratio
Percentage of unused commitment fee, per annum		0.25%
Secured Revolving Credit Agreement (Credit Facility)
Line of Credit Facility [Line Items]
Revolving line of credit borrowing capacity		$ 75.0
Additional borrowing capacity under revolving line of credit		25.0
Amount provided by credit agreement	15.0	0
Revolving line of credit interest rate, per annum	1.00%
Letters of credit amount outstanding		0.2
Remaining amount available under revolving line of credit		$ 74.8
LIBOR | Minimum
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate		0.75%
LIBOR | Maximum
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate		1.25%
Lender's Prime Rate | Minimum
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate		0.00%
Lender's Prime Rate | Maximum
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate		0.25%

XML

Schedule of Acquisition of Hospitalist Practices (Detail) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Business Acquisition [Line Items]
Goodwill	$ 32,142,000
Other intangible assets	677,000
Total acquired assets	32,819,000
2012 transactions	(17,664,000)
Contingent consideration	(15,660,000)
Other - prior year transactions	(24,000)
Total cash paid for acquisitions	(33,348,000)
Decrease in payables for practice acquisitions	(529,000)
Net change in fair value of contingent consideration	511,000
Net change in payables for practice acquisitions	(18,000)
Payables for practice acquisitions, beginning of period	23,706,000	23,724,000
Payables for practice acquisitions, end of period	$ 23,706,000	$ 23,724,000

XML

Schedule of Income Tax Provisions and Effective Tax Rates (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Income tax provision	$ 4,501	$ 3,961	$ 14,309	$ 12,693
Effective tax rate	36.60%	38.00%	37.20%	38.00%

XML

Income Taxes - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2012
Statutory U.S. federal income tax rate	35.00%

XML

Debt

9 Months Ended

Sep. 30, 2012

Debt

Note 3. Debt

Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $75.0 million and contains an “accordion” feature that allows an increase of $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. In March 2012, we borrowed $15.0 million under the Credit Facility bearing interest at 1.0% per annum, which was repaid during the second quarter 2012. As of September 30, 2012, we had no borrowings outstanding, letters of credit of $0.2 million outstanding and $74.8 million available under the Credit Facility.

The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.25%, or the lender’s prime rate plus 0% to 0.25%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date.

The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of September 30, 2012, we were in compliance with such financial covenants and restrictions.

XML

Stock-Based Compensation - Additional Information (Detail)			9 Months Ended
	Sep. 30, 2012	Jun. 07, 2012	Sep. 30, 2012 Stock Options	Sep. 30, 2012 Restricted Stock Awards	Sep. 30, 2012 Minimum Performance Stock Awards	Sep. 30, 2012 Maximum Performance Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved for issuance under stock-based employee compensation program	4,943,170
Common stock available for issuance under equity plan	1,425,666	1,422,130
Vesting period, in years			4 years	4 years	2 years	3 years

XML

Reconciliation for Liabilities Measured at Fair Value on Recurring Basis using Significant Unobservable Inputs (Level 3) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012
Beginning balance	$ 17,191	$ 23,624
Addition through acquisition transactions	6,537	15,155
Change in fair value realized	(3)	511
Payments	(95)	(15,660)
Ending balance	$ 23,630	$ 23,630

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 25,236	$ 17,752
Accounts receivable, net	75,763	68,010
Insurance receivable for malpractice claims - current portion	10,075	8,693
Prepaid expenses and other current assets	8,028	13,139
Total current assets	119,102	107,594
Property and equipment, net	5,911	5,112
Goodwill	205,830	173,688
Other intangible assets, net	1,797	1,812
Deferred tax assets, net	1,522	1,522
Insurance receivable for malpractice claims - less current portion	17,685	15,186
Total assets	351,847	304,914
Current liabilities:
Accounts payable and accrued liabilities	3,776	3,962
Accrued compensation	29,437	21,640
Payables for practice acquisitions	23,706	23,724
Medical malpractice and self-insurance reserves, current portion	10,762	9,383
Deferred tax liabilities	750	750
Total current liabilities	68,431	59,459
Medical malpractice and self-insurance reserves, less current portion	37,274	32,803
Total liabilities	105,705	92,262
Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued	0	0
Common stock, $0.001 par value, 50,000,000 shares authorized, 16,682,186 and 16,474,988 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively	17	16
Additional paid-in capital	148,931	139,579
Retained earnings	97,194	73,057
Total stockholders' equity	246,142	212,652
Total liabilities and stockholders' equity	$ 351,847	$ 304,914

XML

Operations and Significant Accounting Policies

9 Months Ended

Sep. 30, 2012

Operations and Significant Accounting Policies

Note 1. Operations and Significant Accounting Policies

Business

IPC The Hospitalist Company, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time hospitalist practices. Hospitalists focus on a patient’s care from the time of admission to discharge, working in close consultation with primary care physicians, other referring physicians and medical providers to coordinate the inpatient care delivery system and manage the entire inpatient episode of care. Our affiliated hospitalists practice in inpatient facilities, including acute care hospitals, long-term acute care facilities, specialty hospitals, psychiatric facilities and post-acute care facilities. The physicians are primarily full-time employees of our subsidiaries or consolidated professional medical corporations managed under long-term management agreements (Professional Medical Corporations), although part-time and temporary physicians are also employed or contracted on an as-needed basis. Also, unless otherwise expressly stated or the context otherwise requires, “our affiliated hospitalists” refer to physicians, nurse practitioners and physician assistants employed or contracted by either our wholly-owned subsidiaries or our Professional Medical Corporations. References to “practices” or “practice groups” refer to our Professional Medical Corporations and the wholly-owned subsidiaries of IPC that provide medical services, unless otherwise expressly stated or the context otherwise requires.

We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. In our opinion, these financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the following disclosures, when read in conjunction with the audited consolidated financial statements and notes thereto as of December 31, 2011, are adequate to make the information presented not misleading. For further information, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the SEC on February 23, 2012.

Principles of Consolidation

Our consolidated financial statements include the accounts of IPC The Hospitalist Company, Inc. and its wholly owned subsidiaries and consolidated Professional Medical Corporations managed under long-term management agreements. Some states have laws that prohibit business entities, such as IPC, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the “corporate practice of medicine”), or engaging in certain arrangements with physicians, such as fee-splitting. In states that have these restrictions, we operate by maintaining long-term management contracts with the Professional Medical Corporations, which are each owned and operated by physicians, and which employ or contract with additional physicians to provide hospitalist services. Under the management agreements, we provide and perform all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. The management agreements have an initial term of 20 years and are automatically renewable for successive 10-year periods unless terminated by either party for cause. The management agreements are not terminable by the Professional Medical Corporations, except in the case of gross negligence, fraud, or other illegal acts by us, or bankruptcy of IPC.

Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have controls over the operations of these VIE’s. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment.

The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2012.

Fair Value of Financial Instruments

The carrying amounts of our cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

Accounts Receivable and Concentration of Credit Risk

For the nine months ended September 30, 2012 and 2011, total patient volume consisted of the following percentage from Medicare and Medicaid programs:

	Nine Months Ended September 30,
	2012			2011
Medicare and Medicaid patients		52	%		51	%

Our accounts receivable are stated at the amounts expected to be collected. Except with respect to the Medicare and Medicaid programs, concentrations of credit risk, which consist primarily of accounts receivable, is limited due to the large number of payors that compose our diverse payor mix and patient base. Accounts receivable from Medicare and Medicaid made up the following percentage of total net accounts receivable:

	September 30, 2012			December 31, 2011
Percentage of receivables from Medicare and Medicaid		36	%		36	%

Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill for the nine months ended September 30, 2012 are as follows (in thousands):

Goodwill - beginning balance at January 1, 2012	$	173,688
Goodwill acquired during period		32,142
Goodwill - ending balance at September 30, 2012	$	205,830

Medical Malpractice Liability Insurance

We maintain medical malpractice insurance coverage that indemnifies us and our employed health care professionals on a claims-made basis. Our claims-made coverage covers those claims reported during the policy period, which ends December 31 of each year, on a first dollar coverage up to our policy limits on new claims reported during the policy period. In December 2011, we renewed our annual professional liability insurance policy for 2012 effective January 1, 2012 under the same terms as our 2011 policy. We expect to be able to continue to obtain coverage in future years; however, there can be no assurance that we will obtain substantially similar coverage as is provided under the 2012 policy at acceptable costs and on favorable terms upon expiration.

We record our medical malpractice reserves, on an undiscounted basis, for self-insured deductibles, claims incurred and reported and claims incurred but not reported during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP.

Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

	September 30, 2012								December 31, 2011
	Assets		Liabilities						Assets		Liabilities
	Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities		Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities
Current Portion	$	10,075	$	10,252		510		10,762	$	8,693	$	8,956		427		9,383
Long-term Portion		17,685		17,685		19,589		37,274		15,186		15,186		17,617		32,803
Total	$	27,760	$	27,937		20,099		48,036	$	23,879	$	24,142		18,044		42,186

Recently Adopted Accounting Principles

In September 2011, the Financial Accounting Standard Board (FASB) issued a GAAP update on goodwill to allow an entity the option of performing a qualitative assessment before calculating the fair value of the reporting unit when testing goodwill for impairment. If the qualitative assessment concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the entity shall perform the quantitative two-step goodwill impairment test. Otherwise, the two-step goodwill impairment test is not required. We adopted this revised GAAP effective on January 1, 2012. The adoption of this revised GAAP does not have a material effect on our financial position, results of operations or cash flows.

In July 2011, the FASB issued a GAAP update on revenue recognition for certain health care entities that recognize significant amounts of patient service revenue without assessing the patient’s ability to pay. This revised GAAP requires such health care entities to present the provision for bad debt related to patient service revenue as a deduction from patient service revenue (net of contractual allowance and discounts) on their statement of income. It also requires additional disclosures of patient service revenue as well as qualitative and quantitative information about changes in the allowance for doubtful accounts. We adopted this revised GAAP effective on January 1, 2012. The adoption of this revised GAAP does not have a material effect on our financial position, results of operations or cash flows as we do not recognize a significant amount of revenue at the time services are rendered without assessing the patient’s ability to pay.

In May 2011, the FASB issued a GAAP update on fair value measurement, which eliminates certain differences between U.S. GAAP and International Financial Reporting Standards (IFRS), resulting in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between GAAP and IFRS. It also expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. We adopted this revised GAAP effective on January 1, 2012. The adoption of this revised GAAP does not have a material effect on our financial position, results of operations or cash flows.

XML

Schedule of Fair Value of Each Option Grant Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Detail)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Risk-free interest rate	1.21%	2.55%
Expected volatility	39.86%	39.34%
Expected option life (in years)	6 years 1 month 28 days	6 years 1 month 28 days
Expected dividend yield	0.00%	0.00%

XML

Operations and Significant Accounting Policies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2012
Accounting Policies [Line Items]
Initial term period of management agreements in years	20 years
Renewal term period of agreements in years	10 years

XML

Summary of Activity in Equity Plan (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	9 Months Ended
	Sep. 30, 2012
Weighted Average Fair Value, Options outstanding as of December 31, 2011	$ 11.02
Weighted Average Fair Value, Granted	$ 14.96
Weighted Average Fair Value, Exercised	$ 7.23
Weighted Average Fair Value, Cancelled/Forfeited	$ 0.27
Weighted Average Fair Value, Expired	$ 0.14
Weighted Average Fair Value, Options outstanding as of September 30, 2012	$ 11.91
Weighted Average Fair Value, Options exercisable as of September 30, 2012	$ 9.62
Aggregate Intrinsic Value, Options outstanding as of September 30, 2012	$ 28,723
Aggregate Intrinsic Value, Options exercisable as of September 30, 2012	$ 23,676
Shares, Options outstanding as of December 31, 2011	1,581,332
Shares, Granted	216,800
Shares, Exercised	(152,074)
Shares, Forfeited	(856)
Shares, Expired	(2,680)
Shares, Options outstanding as of September 30, 2012	1,642,522
Shares, Options exercisable as of September 30, 2012	1,028,439
Weighted-Average Exercise Price, Options outstanding as of December 31, 2011	$ 25.92
Weighted-Average Exercise Price, Granted	$ 37.29
Weighted-Average Exercise Price, Exercised	$ 17.29
Weighted-Average Exercise Price, Cancelled/Forfeited	$ 1.40
Weighted-Average Exercise Price, Expired	$ 0.77
Weighted-Average Exercise Price, Options outstanding as of September 30, 2012	$ 28.27
Weighted-Average Exercise Price, Options exercisable as of September 30, 2012	$ 22.72
Weighted-Average Remaining Contractual Term, Options outstanding as of September 30, 2012 (Years)	7 years 2 months 1 day
Weighted-Average Remaining Contractual Term, Options exercisable as of September 30, 2012 (Years)	6 years 4 months 28 days

XML

Schedule of Medicare and Medicaid Percentage of Total Net Accounts Receivable (Detail)	Sep. 30, 2012	Dec. 31, 2011
Receivables [Line Items]
Percentage of receivables from Medicare and Medicaid	36.00%	36.00%

XML

Acquisitions

9 Months Ended

Sep. 30, 2012

Acquisitions

Note 2. Acquisitions

We recognize all of the assets acquired, liabilities assumed and any contingent consideration at the acquisition-date fair value and expense all transaction related costs.

In connection with the acquisition of hospitalist physician practices, we generally record goodwill and other identifiable intangible assets consisting of physician and hospital agreements, which are amortized for tax purpose over 15 years. The results of operations of the acquired practices are included in the consolidated financial statements from the date of acquisition. In addition to the initial consideration paid at the close of these transactions, the asset purchase agreements generally provide for future consideration to be paid based upon the achievement of certain operating results of the acquired practices as of specified measurement dates. These additional payments are not contingent upon the future employment of the sellers. The estimated fair value of additional future consideration is recognized at the acquisition-date. Subsequent changes, if any, to the acquisition-date fair value are recognized as part of on-going operations.

During the nine months ended September 30, 2012, we completed the acquisition of assets of seven hospitalist physician practices. In addition to the initial consideration paid at the close of these transactions, five of the asset purchase agreements provide for additional consideration to be paid based upon the future operating results of the acquired practices as of specified measurement dates. The contingent consideration for one acquisition was recorded on a provisional basis as of September 30, 2012, pending completion of the valuation study as of the acquisition date.

The following table summarizes the total amounts recorded during the nine months ended September 30, 2012, related to the acquisition of hospitalist practices (in thousands):

Acquired assets – paid and accrued:
Goodwill	$	32,142
Other intangible assets		677
Total acquired assets		32,819
Cash paid for acquisitions:
2012 transactions		(17,664	)
Contingent consideration		(15,660	)
Other - prior year transactions		(24	)
Total cash paid for acquisitions		(33,348	)
Decrease in payables for practice acquisitions		(529	)
Net change in fair value of contingent consideration		511
Net change in payables for practice acquisitions		(18	)
Payables for practice acquisitions, beginning of period		23,724
Payables for practice acquisitions, end of period	$	23,706

Our payable for practice acquisitions balance of $23,706,000 at September 30, 2012 is composed of $23,630,000 of accrued contingent consideration measured at fair value and $76,000 of liabilities recorded at undiscounted carrying value which approximates fair value.

XML

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	16,682,186	16,474,988
Common stock, shares outstanding	16,682,186	16,474,988

XML

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Acquisition of Hospitalist Practices

The following table summarizes the total amounts recorded during the nine months ended September 30, 2012, related to the acquisition of hospitalist practices (in thousands):

Acquired assets – paid and accrued:
Goodwill	$	32,142
Other intangible assets		677
Total acquired assets		32,819
Cash paid for acquisitions:
2012 transactions		(17,664	)
Contingent consideration		(15,660	)
Other - prior year transactions		(24	)
Total cash paid for acquisitions		(33,348	)
Decrease in payables for practice acquisitions		(529	)
Net change in fair value of contingent consideration		511
Net change in payables for practice acquisitions		(18	)
Payables for practice acquisitions, beginning of period		23,724
Payables for practice acquisitions, end of period	$	23,706

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2012	Oct. 23, 2012
Entity Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Trading Symbol	IPCM
Entity Registrant Name	IPC The Hospitalist Company, Inc.
Entity Central Index Key	0001410471
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		16,682,887

XML

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Income Tax Provisions and Effective Tax Rates

Following are the income tax provisions and effective tax rates for the three and nine months ended September 30, 2012 and 2011 (dollars in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Income tax provision	$	4,501		$	3,961		$	14,309		$	12,693
Effective tax rate		36.6	%		38.0	%		37.2	%		38.0	%

XML

Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net revenue	$ 127,651	$ 114,485	$ 385,916	$ 339,604
Operating expenses:
Cost of services-physician practice salaries, benefits and other	93,570	84,920	282,675	248,801
General and administrative	20,689	18,081	61,195	54,275
Net change in fair value of contingent consideration	(3)	178	511	658
Depreciation and amortization	1,027	824	2,848	2,374
Total operating expenses	115,283	104,003	347,229	306,108
Income from operations	12,368	10,482	38,687	33,496
Investment income	3	3	11	12
Interest expense	(78)	(62)	(252)	(106)
Income before income taxes	12,293	10,423	38,446	33,402
Income tax provision	4,501	3,961	14,309	12,693
Net income	$ 7,792	$ 6,462	$ 24,137	$ 20,709
Net income per share:
Basic	$ 0.47	$ 0.39	$ 1.46	$ 1.27
Diluted	$ 0.46	$ 0.38	$ 1.42	$ 1.23

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies

Note 7. Commitments and Contingencies

Legal

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated hospitalists. We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs.

We believe, based upon our review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, or cash flows in a future period.

Government Inquiry

On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We have produced responsive documents, will discuss with representatives of the government additional future productions to be made if requested and will continue to cooperate in the government investigation. We have been informed by the DOJ that a qui tam whistleblower complaint related to this investigation naming the Company has been filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also have been informed that several state attorneys general are examining our Medicaid claims in coordination with the DOJ. It is not possible to predict whether or when this matter may be resolved or what impact, if any, the outcome of this matter might have on our consolidated financial position, results of operations, or cash flows.

XML

Earnings Per Share

9 Months Ended

Sep. 30, 2012

Earnings Per Share

Note 6. Earnings Per Share

Basic net income per share is calculated by dividing net income for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income for the period by the weighted average number of shares outstanding during the period plus the dilutive effect of our outstanding stock awards and shares issuable under our employee stock purchase plan using the treasury stock method.

The calculations of basic and diluted net income per share for the three and nine months ended September 30, 2012 and 2011 are as follows (dollars in thousands, except for per share data):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Basic:
Net income	$	7,792	$	6,462	$	24,137	$	20,709
Weighted average number of common shares outstanding		16,616,866		16,419,071		16,556,061		16,370,878
Basic net income per share	$	0.47	$	0.39	$	1.46	$	1.27
Diluted:
Net income	$	7,792	$	6,462	$	24,137	$	20,709
Weighted average number of common shares outstanding		16,616,866		16,419,071		16,556,061		16,370,878
Weighted average number of dilutive common shares equivalents		443,982		423,176		385,707		433,426
Common shares and common share equivalents		17,060,848		16,842,247		16,941,768		16,804,304
Diluted net income per share	$	0.46	$	0.38	$	1.42	$	1.23

Outstanding stock options with an exercise price above market are excluded from our diluted computation as their effect would be anti-dilutive. As of September 30, 2012, there were approximately 431,000 outstanding stock options with an exercise price above the average market price for the nine months ended September 30, 2012.

XML

Schedule of Medicare and Medicaid Percentage of Total Patient Volume (Detail)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Receivables [Line Items]
Medicare and Medicaid patients	52.00%	51.00%

XML

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Stock-Based Compensation Expense Recognized when Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested

Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2012		2011		2012		2011
Stock-based compensation expense	$	1,626	$	1,222	$	4,714	$	3,473

Schedule of Total Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted Under Equity Plan and Weighted-Average Period of Years Expected to Recognize those Costs

As of September 30, 2012, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands).

	Total Unrecognized Compensation Cost		Weighted -average Remaining Contractual Term
			(Years)
Stock option	$	8,469		7.17
Restricted/Performance stock	$	2,813		3.00

Schedule of Fair Value of Each Option Grant Estimated on Date of Grant Using Black-Scholes Option-Pricing Model

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:

	Nine months ended September 30,
	2012			2011
Risk-free interest rate		1.21	%		2.55	%
Expected volatility		39.86	%		39.34	%
Expected option life (in years)		6.16			6.16
Expected dividend yield		0.00	%		0.00	%

Summary of Activity in Equity Plan

The following table summarizes the stock option activities in our Equity Plan during the nine months ended September 30, 2012.

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
						(Years)		(in ,000)
Options outstanding as of December 31, 2011		1,581,332		$	25.92					$	11.02
Changes during period:
Granted		216,800			37.29						14.96
Exercised		(152,074	)		17.29						7.23
Cancelled/Forfeited		(856	)		1.40						0.27
Expired		(2,680	)		0.77						0.14
Options outstanding as of September 30, 2012		1,642,522		$	28.27		7.17	$	28,723	$	11.91
Options exercisable as of September 30, 2012		1,028,439		$	22.72		6.41	$	23,676	$	9.62

Summary of Restricted Stock Awards and Performance Stock Awards Activities in Equity Plan

The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the nine months ended September 30, 2012.

	Shares			Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
				(Years)		(in ,000)
Restricted/performance stock awards outstanding as of December 31, 2011		31,496						$	40.87
Changes during period:
Granted		80,535							36.57
Released		(8,085	)						35.03
Restricted/performance stock awards outstanding as of September 30, 2012		103,946			3.00	$	4,750	$	37.99

XML

Operations and Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2012

Business

Business

IPC The Hospitalist Company, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time hospitalist practices. Hospitalists focus on a patient’s care from the time of admission to discharge, working in close consultation with primary care physicians, other referring physicians and medical providers to coordinate the inpatient care delivery system and manage the entire inpatient episode of care. Our affiliated hospitalists practice in inpatient facilities, including acute care hospitals, long-term acute care facilities, specialty hospitals, psychiatric facilities and post-acute care facilities. The physicians are primarily full-time employees of our subsidiaries or consolidated professional medical corporations managed under long-term management agreements (Professional Medical Corporations), although part-time and temporary physicians are also employed or contracted on an as-needed basis. Also, unless otherwise expressly stated or the context otherwise requires, “our affiliated hospitalists” refer to physicians, nurse practitioners and physician assistants employed or contracted by either our wholly-owned subsidiaries or our Professional Medical Corporations. References to “practices” or “practice groups” refer to our Professional Medical Corporations and the wholly-owned subsidiaries of IPC that provide medical services, unless otherwise expressly stated or the context otherwise requires.

We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. In our opinion, these financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the following disclosures, when read in conjunction with the audited consolidated financial statements and notes thereto as of December 31, 2011, are adequate to make the information presented not misleading. For further information, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the SEC on February 23, 2012.

Principles of Consolidation

Principles of Consolidation

Our consolidated financial statements include the accounts of IPC The Hospitalist Company, Inc. and its wholly owned subsidiaries and consolidated Professional Medical Corporations managed under long-term management agreements. Some states have laws that prohibit business entities, such as IPC, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the “corporate practice of medicine”), or engaging in certain arrangements with physicians, such as fee-splitting. In states that have these restrictions, we operate by maintaining long-term management contracts with the Professional Medical Corporations, which are each owned and operated by physicians, and which employ or contract with additional physicians to provide hospitalist services. Under the management agreements, we provide and perform all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. The management agreements have an initial term of 20 years and are automatically renewable for successive 10-year periods unless terminated by either party for cause. The management agreements are not terminable by the Professional Medical Corporations, except in the case of gross negligence, fraud, or other illegal acts by us, or bankruptcy of IPC.

Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have controls over the operations of these VIE’s. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment.

The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2012.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying amounts of our cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

Accounts Receivable and Concentration of Credit Risk

Accounts Receivable and Concentration of Credit Risk

For the nine months ended September 30, 2012 and 2011, total patient volume consisted of the following percentage from Medicare and Medicaid programs:

	Nine Months Ended September 30,
	2012			2011
Medicare and Medicaid patients		52	%		51	%

Our accounts receivable are stated at the amounts expected to be collected. Except with respect to the Medicare and Medicaid programs, concentrations of credit risk, which consist primarily of accounts receivable, is limited due to the large number of payors that compose our diverse payor mix and patient base. Accounts receivable from Medicare and Medicaid made up the following percentage of total net accounts receivable:

	September 30, 2012			December 31, 2011
Percentage of receivables from Medicare and Medicaid		36	%		36	%

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill for the nine months ended September 30, 2012 are as follows (in thousands):

Goodwill - beginning balance at January 1, 2012	$	173,688
Goodwill acquired during period		32,142
Goodwill - ending balance at September 30, 2012	$	205,830

Medical Malpractice Liability Insurance

Medical Malpractice Liability Insurance

We maintain medical malpractice insurance coverage that indemnifies us and our employed health care professionals on a claims-made basis. Our claims-made coverage covers those claims reported during the policy period, which ends December 31 of each year, on a first dollar coverage up to our policy limits on new claims reported during the policy period. In December 2011, we renewed our annual professional liability insurance policy for 2012 effective January 1, 2012 under the same terms as our 2011 policy. We expect to be able to continue to obtain coverage in future years; however, there can be no assurance that we will obtain substantially similar coverage as is provided under the 2012 policy at acceptable costs and on favorable terms upon expiration.

We record our medical malpractice reserves, on an undiscounted basis, for self-insured deductibles, claims incurred and reported and claims incurred but not reported during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP.

XML

Fair Value Measurement

9 Months Ended

Sep. 30, 2012

Fair Value Measurement

Note 8. Fair Value Measurement

Some of our assets and liabilities are measured and recorded at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The established fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (Levels 1 and 2) and the reporting entity’s own assumptions about market participant assumptions (Level 3). This hierarchy is used to measure fair value as follows:

• Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities.

• Level 2 inputs include quoted prices for similar assets and liabilities in active markets; quoted prices in markets that are not active; and other inputs that are observable or can be corroborated by observable market data for the asset or liability.

• Level 3 inputs are unobservable inputs for the asset or liability that are supported by little or no market activity.

The following table presents our liabilities measured at fair value on a recurring basis as of September 30, 2012 (in thousands):

	Quoted Price In Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Balance
Accrued contingent consideration for practice acquisitions (included in payables for practice acquisitions)	$	0	$	0	$	23,630	$	23,630

The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) for the three and nine months ended September 30, 2012 (in thousands):

	Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
Accrued contingent consideration for practice acquisitions
Beginning balance	$	17,191		$	23,624
Addition through acquisition transactions		6,537			15,155
Change in fair value realized		(3	)		511
Payments		(95	)		(15,660	)
Ending balance	$	23,630		$	23,630

Our payable for practice acquisitions totaling $23,706,000 at September 30, 2012, is composed of $23,630,000 of accrued contingent consideration measured at fair value and $76,000 of liabilities recorded at undiscounted carrying value which approximates fair value. The fair value of our accrued contingent consideration is determined using widely accepted valuation techniques, which include the income approach for estimating future consideration to be paid based on projected earnings of our acquired practices as of specified measurement dates. The income approach involves the use of a probability-weighted discounted cash flow model based on significant inputs not observable in the market. The significant inputs include a discount rate of 2.6%, and 100% probability of achieving the estimated projected earnings.

Because our accrued contingent consideration is generally based on a certain multiple of earnings of the acquired practices during a specified measurement period, a relatively small change in such projected earnings may result in a material change to the fair value of such contingent consideration liability with a corresponding adjustment to income from operations. We reassess our projected earnings and the related fair value of our accrued contingent consideration for practice acquisitions on a quarterly basis.

XML

Subsequent Events

9 Months Ended

Sep. 30, 2012

Subsequent Events

Note 9. Subsequent Events

Subsequent to September 30, 2012, we acquired the assets of two hospitalist physician practices.

XML

Operations and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Medicare and Medicaid Percentage of Total Patient Volume

For the nine months ended September 30, 2012 and 2011, total patient volume consisted of the following percentage from Medicare and Medicaid programs:

	Nine Months Ended September 30,
	2012			2011
Medicare and Medicaid patients		52	%		51	%

Schedule of Medicare and Medicaid Percentage of Total Net Accounts Receivable

Accounts receivable from Medicare and Medicaid made up the following percentage of total net accounts receivable:

	September 30, 2012			December 31, 2011
Percentage of receivables from Medicare and Medicaid		36	%		36	%

Schedule of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the nine months ended September 30, 2012 are as follows (in thousands):

Goodwill - beginning balance at January 1, 2012	$	173,688
Goodwill acquired during period		32,142
Goodwill - ending balance at September 30, 2012	$	205,830

Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables

Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

	September 30, 2012								December 31, 2011
	Assets		Liabilities						Assets		Liabilities
	Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities		Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities
Current Portion	$	10,075	$	10,252		510		10,762	$	8,693	$	8,956		427		9,383
Long-term Portion		17,685		17,685		19,589		37,274		15,186		15,186		17,617		32,803
Total	$	27,760	$	27,937		20,099		48,036	$	23,879	$	24,142		18,044		42,186

XML

Schedule of Total Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted Under Equity Plan and Weighted-Average Period of Years (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Unrecognized Compensation Cost	$ 8,469
Weighted -average Remaining Contractual Term (Years)	7 years 2 months 1 day
Restricted/Performance Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Unrecognized Compensation Cost	$ 2,813
Weighted -average Remaining Contractual Term (Years)	3 years

XML

Fair Value Measurement (Tables)

9 Months Ended

Sep. 30, 2012

Liabilities Measured at Fair Value on Recurring Basis

The following table presents our liabilities measured at fair value on a recurring basis as of September 30, 2012 (in thousands):

	Quoted Price In Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Balance
Accrued contingent consideration for practice acquisitions (included in payables for practice acquisitions)	$	0	$	0	$	23,630	$	23,630

Reconciliation for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)

The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) for the three and nine months ended September 30, 2012 (in thousands):

	Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
Accrued contingent consideration for practice acquisitions
Beginning balance	$	17,191		$	23,624
Addition through acquisition transactions		6,537			15,155
Change in fair value realized		(3	)		511
Payments		(95	)		(15,660	)
Ending balance	$	23,630		$	23,630

XML

Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Malpractice Insurance [Line Items]
Insurance receivable for malpractice claims-current portion	$ 10,075	$ 8,693
Insurance receivable for malpractice claims-less current portion	17,685	15,186
Insurance Receivable, Total	27,760	23,879
Claims Reserve, Current Portion	10,252	8,956
Claims Reserve, Long-term Portion	17,685	15,186
Claims Reserve, Total	27,937	24,142
IBNR Reserve, Current Portion	510	427
IBNR Reserve, Long-term Portion	19,589	17,617
IBNR Reserve, Total	20,099	18,044
Medical malpractice and self-insurance reserves, current portion	10,762	9,383
Medical malpractice and self-insurance reserves, less current portion	37,274	32,803
Total Liabilities	$ 48,036	$ 42,186

XML

Fair Value Measurement - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Payables for practice acquisitions balance	$ 23,706,000	$ 23,724,000
Business acquisition, contingent consideration, payables	23,630,000
Business acquisition, liabilities recorded at undiscounted carrying value	$ 76,000
Discount rate on significant inputs	2.60%
Probability of achieving estimated projected earnings	100.00%

XML

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Operating activities
Net income	$ 24,137	$ 20,709
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,848	2,374
Stock-based compensation expense	4,714	3,473
Net change in fair value of contingent consideration	511	658
Changes in assets and liabilities:
Accounts receivable	(7,753)	(8,736)
Prepaid expenses and other current assets	5,111	4,994
Accounts payable and accrued liabilities	(241)	5
Accrued compensation	7,797	4,779
Medical malpractice and self-insurance reserves, net	1,969	2,777
Net cash provided by operating activities	39,093	31,033
Investing activities
Acquisitions of physician practices	(33,348)	(19,387)
Purchase of property and equipment	(2,955)	(2,075)
Net cash used in investing activities	(36,303)	(21,462)
Financing activities
Proceeds from long-term debt	15,000	0
Repayment of long-term debt	(15,000)	0
Net proceeds from issuance of common stock	3,711	2,352
Excess tax benefits from stock-based compensation	983	1,177
Net cash provided by financing activities	4,694	3,529
Net increase in cash and cash equivalents	7,484	13,100
Cash and cash equivalents, beginning of period	17,752	18,935
Cash and cash equivalents, end of period	25,236	32,035
Cash paid for:
Interest	251	107
Income taxes	$ 14,352	$ 11,843

XML

Stock-Based Compensation

9 Months Ended

Sep. 30, 2012

Stock-Based Compensation

Note 5. Stock-Based Compensation

At September 30, 2012, we had a stock-based employee compensation program, for which we had reserved a total of 4,943,170 common shares for issuance under our 2007 and 2012 Equity Participation Plans (Equity Plan). Pursuant to our 2012 Equity Participation Plan, which was approved by our stockholders on June 7, 2012, a total of 1,422,130 shares of our common stock are available for issuance under such plan. Subsequent to the approval of our 2012 Equity Participation Plan, no new awards will be issued under the 2007 Equity Participation Plan. As of September 30, 2012, there were 1,425,666 shares of our common stock available for issuance under our Equity Plan, which included the canceled and forfeited shares issued prior to our 2012 Equity Participation Plan.

All option awards granted during the nine months ended September 30, 2012 were issued with exercise prices equal to the closing price of our common stock on the NASDAQ Global Select Market on the dates of grant. The options under our Equity Plan generally vest over a four-year period from date of grant, and unrestricted options terminate on the 10th anniversary of the agreement date. Restricted stock awards generally vest over a four-year period from date of the award and performance stock awards generally vest over two to three years from date of the award.

Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2012		2011		2012		2011
Stock-based compensation expense	$	1,626	$	1,222	$	4,714	$	3,473

As of September 30, 2012, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands).

	Total Unrecognized Compensation Cost		Weighted -average Remaining Contractual Term
			(Years)
Stock option	$	8,469		7.17
Restricted/Performance stock	$	2,813		3.00

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:

	Nine months ended September 30,
	2012			2011
Risk-free interest rate		1.21	%		2.55	%
Expected volatility		39.86	%		39.34	%
Expected option life (in years)		6.16			6.16
Expected dividend yield		0.00	%		0.00	%

The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero coupon issues. The expected volatility is based on historical volatility levels of our public company peer group and the volatility of our stock price since our initial public offering in January 2008. The expected option life of each award granted was calculated using the “simplified method” in accordance with GAAP.

The grant date fair value of each restricted stock award or performance stock award is based on the closing stock price on the grant date of the award as reported by NASDAQ Global Select Market.

The following table summarizes the stock option activities in our Equity Plan during the nine months ended September 30, 2012.

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
						(Years)		(in ,000)
Options outstanding as of December 31, 2011		1,581,332		$	25.92					$	11.02
Changes during period:
Granted		216,800			37.29						14.96
Exercised		(152,074	)		17.29						7.23
Cancelled/Forfeited		(856	)		1.40						0.27
Expired		(2,680	)		0.77						0.14
Options outstanding as of September 30, 2012		1,642,522		$	28.27		7.17	$	28,723	$	11.91
Options exercisable as of September 30, 2012		1,028,439		$	22.72		6.41	$	23,676	$	9.62

The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the nine months ended September 30, 2012.

	Shares			Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value		Weighted- Average Fair Value
				(Years)		(in ,000)
Restricted/performance stock awards outstanding as of December 31, 2011		31,496						$	40.87
Changes during period:
Granted		80,535							36.57
Released		(8,085	)						35.03
Restricted/performance stock awards outstanding as of September 30, 2012		103,946			3.00	$	4,750	$	37.99

XML

Acquisitions - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2012 Hospitalist	Dec. 31, 2011
Business Acquisition [Line Items]
Identifiable intangible assets amortization period	15 years
Number of hospitalist physician practices acquired	7
Payables for practice acquisitions balance	$ 23,706,000	$ 23,724,000
Business acquisition, contingent consideration, payables	23,630,000
Business acquisition, liabilities recorded at undiscounted carrying value	$ 76,000

XML

Schedule of Basic and Diluted Net Income Per Share (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Basic:
Net income	$ 7,792	$ 6,462	$ 24,137	$ 20,709
Weighted average number of common shares outstanding	16,616,866	16,419,071	16,556,061	16,370,878
Basic net income per share	$ 0.47	$ 0.39	$ 1.46	$ 1.27
Diluted:
Net income	$ 7,792	$ 6,462	$ 24,137	$ 20,709
Weighted average number of common shares outstanding	16,616,866	16,419,071	16,556,061	16,370,878
Weighted average number of dilutive common shares equivalents	443,982	423,176	385,707	433,426
Common shares and common share equivalents	17,060,848	16,842,247	16,941,768	16,804,304
Diluted net income per share	$ 0.46	$ 0.38	$ 1.42	$ 1.23
Stock options outstanding excluded from diluted shares computation			431,000

XML

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Basic and Diluted Net Income Per Share

The calculations of basic and diluted net income per share for the three and nine months ended September 30, 2012 and 2011 are as follows (dollars in thousands, except for per share data):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Basic:
Net income	$	7,792	$	6,462	$	24,137	$	20,709
Weighted average number of common shares outstanding		16,616,866		16,419,071		16,556,061		16,370,878
Basic net income per share	$	0.47	$	0.39	$	1.46	$	1.27
Diluted:
Net income	$	7,792	$	6,462	$	24,137	$	20,709
Weighted average number of common shares outstanding		16,616,866		16,419,071		16,556,061		16,370,878
Weighted average number of dilutive common shares equivalents		443,982		423,176		385,707		433,426
Common shares and common share equivalents		17,060,848		16,842,247		16,941,768		16,804,304
Diluted net income per share	$	0.46	$	0.38	$	1.42	$	1.23